HIF2α contributes to antiestrogen resistance via positive bilateral crosstalk with EGFR in breast cancer cells

The majority of breast cancers express estrogen receptor α (ERα), and most patients with ERα-positive breast cancer benefit from antiestrogen therapy. The ERα-modulator tamoxifen and ERα-downregulator fulvestrant are commonly employed antiestrogens. Antiestrogen resistance remains a clinical challen...

Descripción completa

Detalles Bibliográficos
Autores principales: Alam, Muhammad Wasi, Persson, Camilla Ulrika, Reinbothe, Susann, Kazi, Julhash U., Rönnstrand, Lars, Wigerup, Caroline, Ditzel, Henrik Jorn, Lykkesfeldt, Anne E., Påhlman, Sven, Jögi, Annika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905469/
https://www.ncbi.nlm.nih.gov/pubmed/26849233
http://dx.doi.org/10.18632/oncotarget.7167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905469/
https://www.ncbi.nlm.nih.gov/pubmed/26849233
http://dx.doi.org/10.18632/oncotarget.7167

Ejemplares similares